Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
Clinical Study of Aprepitant and Ondansetron Monotherapy or Combination in the Treatment of Postoperative Nausea and Vomiting in Thyroid Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Shumin Dong, M.D.
- Phone Number: 18665573591
- Email: dongshumin_zdyfy@163.com
Study Contact Backup
- Name: Detao Yin, M.D.
- Phone Number: 13693717963
- Email: detaoyin@zzu.edu.cn
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 18-80 years;
- Voluntary enrollment in the study and signing the informed consent form;
- Diagnosed with thyroid cancer and needing surgical treatment;
Exclusion Criteria:
- Patient has depression, history of chronic pain, insulin-dependent diabetes mellitus I or II, history of severe vomiting;
- history of prior thyroid or neck surgery;
- Cases in which surgery requiring sternotomy is anticipated;
- History of long-term hormone use, period of immunosuppressive therapy;
- pre-operative voice changes or laryngoscopic confirmation of vocal cord paralysis;
- Pregnant or breastfeeding patients;
- Patients who are allergic to any of the study medications;
- Patients who have received any sedative, hypnotic, anxiolytic, opioid, steroid or other antiemetic medication within 24 hours prior to the procedure;
- Patients taking or planning to take a combination of drugs such as rifampicin, carbamazepine, phenytoin or other drugs that strongly induce CYP3A4 activity;
- patients with other malignant tumors;
- Patients with hypothyroidism;
- Participating or planning to participate in other clinical studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Ondansetron group
Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
|
Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
Other Names:
|
|
Other: Arepitant group
Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
|
Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
Other Names:
|
|
Experimental: Combined treatment group
Patients in the combined group received 125 mg of oral aprepitant plus 8 mg of ondansetron 1 hour before anesthesia, with ondansetron followed by two oral doses of the drug at 8-hour intervals, and 80 mg of aprepitant once daily in the morning on postoperative days 2 and 3 (the day of the surgery was day 1)
|
Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
Other Names:
Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete remission rate (CR rate)
Time Frame: Within 24 hours after surgery
|
Complete remission rate (CR rate) without vomiting within 24h postoperatively and without resolution
|
Within 24 hours after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete remission rate (CR rate)
Time Frame: Within 48 hours after surgery
|
Complete remission rate (CR rate) without vomiting within 48h postoperatively and without resolution
|
Within 48 hours after surgery
|
|
Rate of no vomiting
Time Frame: Within 24 and 48 hours after surgery
|
Rate of no vomiting within 24h, 48h
|
Within 24 and 48 hours after surgery
|
|
Incidence of adverse events and serious adverse events
Time Frame: up to 24 weeks
|
Adverse events and serious adverse events
|
up to 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Detao Yin, M.D., The First Affiliated Hospital of Zhengzhou University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Postoperative Complications
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Signs and Symptoms, Digestive
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Nausea
- Thyroid Diseases
- Vomiting
- Postoperative Nausea and Vomiting
- Thyroid Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Dermatologic Agents
- Neurotransmitter Agents
- Antipruritics
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin Antagonists
- Serotonin Agents
- Neurokinin-1 Receptor Antagonists
- Aprepitant
- Ondansetron
Other Study ID Numbers
Other Study ID Numbers
- HN-PONV-ADR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.